HUS2300021I1 - Anti-IL-36R antitestek - Google Patents
Anti-IL-36R antitestekInfo
- Publication number
- HUS2300021I1 HUS2300021I1 HUS2300021C HUS2300021C HUS2300021I1 HU S2300021 I1 HUS2300021 I1 HU S2300021I1 HU S2300021 C HUS2300021 C HU S2300021C HU S2300021 C HUS2300021 C HU S2300021C HU S2300021 I1 HUS2300021 I1 HU S2300021I1
- Authority
- HU
- Hungary
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161560554P | 2011-11-16 | 2011-11-16 | |
US201261644111P | 2012-05-08 | 2012-05-08 | |
US201261713713P | 2012-10-15 | 2012-10-15 | |
EP12788410.4A EP2780373B1 (en) | 2011-11-16 | 2012-11-14 | Anti il-36r antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HUS2300021I1 true HUS2300021I1 (hu) | 2023-07-28 |
Family
ID=47215803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12788410A HUE047437T2 (hu) | 2011-11-16 | 2012-11-14 | Anti-IL-36R antitestek |
HUS2300021C HUS2300021I1 (hu) | 2011-11-16 | 2023-06-05 | Anti-IL-36R antitestek |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12788410A HUE047437T2 (hu) | 2011-11-16 | 2012-11-14 | Anti-IL-36R antitestek |
Country Status (38)
Country | Link |
---|---|
US (3) | US9023995B2 (hu) |
EP (2) | EP3536710A1 (hu) |
JP (3) | JP6289375B2 (hu) |
KR (3) | KR102038310B1 (hu) |
CN (3) | CN104080808B (hu) |
AP (1) | AP2014007571A0 (hu) |
AR (1) | AR089178A1 (hu) |
AU (1) | AU2012339734B2 (hu) |
BR (1) | BR112014011594B1 (hu) |
CA (1) | CA2852994C (hu) |
CL (1) | CL2014001123A1 (hu) |
CO (1) | CO7020871A2 (hu) |
CY (1) | CY1122278T1 (hu) |
DK (1) | DK2780373T3 (hu) |
EA (1) | EA031948B1 (hu) |
EC (1) | ECSP14004976A (hu) |
ES (1) | ES2755732T3 (hu) |
FI (1) | FIC20230020I1 (hu) |
FR (1) | FR23C1023I2 (hu) |
HR (1) | HRP20191835T1 (hu) |
HU (2) | HUE047437T2 (hu) |
IL (2) | IL232100B (hu) |
LT (2) | LT2780373T (hu) |
MX (1) | MX347164B (hu) |
MY (1) | MY195289A (hu) |
NL (1) | NL301233I2 (hu) |
PE (1) | PE20142041A1 (hu) |
PH (1) | PH12014501108B1 (hu) |
PL (1) | PL2780373T3 (hu) |
PT (1) | PT2780373T (hu) |
RS (1) | RS59248B1 (hu) |
SG (1) | SG11201402283PA (hu) |
SI (1) | SI2780373T1 (hu) |
TW (1) | TWI573804B (hu) |
UA (1) | UA115540C2 (hu) |
UY (1) | UY34456A (hu) |
WO (1) | WO2013074569A1 (hu) |
ZA (1) | ZA201402491B (hu) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE035281T2 (hu) | 2011-01-14 | 2018-05-02 | Univ California | A ROR-1 protein elleni terápiás antitestek és ezek felhasználási módszerei |
EP3536710A1 (en) | 2011-11-16 | 2019-09-11 | Boehringer Ingelheim International GmbH | Anti il-36r antibodies |
BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
KR102442436B1 (ko) * | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
RU2582569C2 (ru) * | 2014-07-24 | 2016-04-27 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
MX2017013080A (es) * | 2015-04-15 | 2018-02-09 | Anaptysbio Inc | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). |
EP3307772B1 (en) * | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
JP6654773B2 (ja) * | 2015-12-25 | 2020-02-26 | 国立大学法人名古屋大学 | インターロイキン36受容体アンタゴニスト欠損症の治療薬 |
MA46113A (fr) | 2016-11-01 | 2019-07-10 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3) |
CN110382000A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗tim-3抗体治疗癌症的方法 |
US20180273627A1 (en) * | 2017-03-27 | 2018-09-27 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
CN111867579B (zh) * | 2018-01-08 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法 |
JP2021517577A (ja) | 2018-03-14 | 2021-07-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症性腸疾患の処置のための抗il−36r抗体の使用 |
MX2020009544A (es) * | 2018-03-14 | 2020-10-05 | Boehringer Ingelheim Int | Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada. |
EP3823989A2 (en) | 2018-07-16 | 2021-05-26 | Regeneron Pharmaceuticals, Inc. | Anti-il36r antibodies |
WO2020018511A1 (en) * | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
JP2022532812A (ja) | 2018-08-16 | 2022-07-20 | カンタージア アクチエボラーグ | 抗il1rap抗体組成物 |
WO2020065594A1 (en) * | 2018-09-28 | 2020-04-02 | Kyowa Kirin Co., Ltd. | Il-36 antibodies and uses thereof |
AU2019405782A1 (en) | 2018-12-21 | 2021-06-17 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
CA3124996A1 (en) | 2018-12-27 | 2020-07-02 | Boehringer Ingelheim International Gmbh | Il-36r antibodies for treatment of palmoplantar pustulosis |
WO2020185479A1 (en) * | 2019-03-08 | 2020-09-17 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibody formulations |
US20220162326A1 (en) * | 2019-05-13 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | Anti-il36r antibodies |
WO2021112196A1 (ja) * | 2019-12-05 | 2021-06-10 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
AR120913A1 (es) * | 2019-12-27 | 2022-03-30 | Teijin Pharma Ltd | Anticuerpo que inhibe específicamente la señalización de il-36r |
CN115666643A (zh) | 2020-05-19 | 2023-01-31 | 勃林格殷格翰国际有限公司 | 用于治疗异位性皮肤炎的抗il-36r抗体 |
CN116745315A (zh) | 2020-07-17 | 2023-09-12 | 勃林格殷格翰国际有限公司 | 用于治疗嗜中性皮肤病的抗il-36r抗体 |
WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
CN116406295A (zh) | 2020-07-30 | 2023-07-07 | 安奈普泰斯生物有限公司 | 针对鱼鳞病的抗白介素36受体(il-36r)疗法 |
CA3192882A1 (en) | 2020-09-30 | 2022-04-07 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
CN116685605A (zh) | 2020-12-17 | 2023-09-01 | 上海华奥泰生物药业股份有限公司 | 靶向il-17a和il-36r的双特异性抗体及其应用 |
WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
CN114907477A (zh) * | 2021-02-08 | 2022-08-16 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
AU2022231135A1 (en) | 2021-03-04 | 2023-07-27 | Boehringer Ingelheim International Gmbh | Methods for the treatment of gpp |
EP4305207A2 (en) | 2021-03-12 | 2024-01-17 | Boehringer Ingelheim International GmbH | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
BR112023017717A2 (pt) * | 2021-05-03 | 2024-01-09 | Boehringer Ingelheim Int | Método para produção de espesolimabe |
AU2022291974A1 (en) * | 2021-06-18 | 2024-01-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-il-36r antibody and use thereof |
WO2023285362A1 (en) | 2021-07-12 | 2023-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
US20230049147A1 (en) | 2021-08-13 | 2023-02-16 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for the treatment of a fibrotic condition |
WO2023052222A2 (en) | 2021-09-28 | 2023-04-06 | Boehringer Ingelheim International Gmbh | System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation |
US11802149B2 (en) | 2021-10-28 | 2023-10-31 | Abbvie Inc. | Anti-amyloid beta antibodies and methods of using the same |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
EP1798287A3 (en) | 1997-08-01 | 2007-11-14 | Schering Corporation | Mammalian cell membrane proteins and related reagents |
US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
ES2637801T3 (es) * | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
EP1627927A3 (en) * | 2001-03-01 | 2006-06-07 | Epigenomics AG | Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
WO2004031362A2 (en) * | 2002-10-03 | 2004-04-15 | Large Scale Biology Corporation | Multimeric protein engineering |
WO2007024715A2 (en) * | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP5577543B2 (ja) | 2006-09-08 | 2014-08-27 | アムジエン・インコーポレーテツド | Il−1ファミリーバリアント |
MX2009011500A (es) | 2007-04-23 | 2010-01-29 | Schering Corp | Anticuerpos anti-mdl-1. |
JP5171948B2 (ja) | 2007-06-29 | 2013-03-27 | メルク・シャープ・アンド・ドーム・コーポレーション | Mdl−1の使用 |
US20110159011A1 (en) | 2008-08-28 | 2011-06-30 | Wyeth Llc | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
EP3536710A1 (en) | 2011-11-16 | 2019-09-11 | Boehringer Ingelheim International GmbH | Anti il-36r antibodies |
MX2017013080A (es) | 2015-04-15 | 2018-02-09 | Anaptysbio Inc | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). |
-
2012
- 2012-11-14 EP EP19169065.0A patent/EP3536710A1/en active Pending
- 2012-11-14 CN CN201280054425.XA patent/CN104080808B/zh active Active
- 2012-11-14 AP AP2014007571A patent/AP2014007571A0/xx unknown
- 2012-11-14 KR KR1020147013267A patent/KR102038310B1/ko active Application Filing
- 2012-11-14 LT LTEP12788410.4T patent/LT2780373T/lt unknown
- 2012-11-14 DK DK12788410T patent/DK2780373T3/da active
- 2012-11-14 AU AU2012339734A patent/AU2012339734B2/en active Active
- 2012-11-14 KR KR1020207026736A patent/KR20200110476A/ko not_active Application Discontinuation
- 2012-11-14 JP JP2014542388A patent/JP6289375B2/ja active Active
- 2012-11-14 WO PCT/US2012/064933 patent/WO2013074569A1/en active Application Filing
- 2012-11-14 ES ES12788410T patent/ES2755732T3/es active Active
- 2012-11-14 BR BR112014011594-0A patent/BR112014011594B1/pt active IP Right Grant
- 2012-11-14 CN CN201610916419.0A patent/CN107007833B/zh active Active
- 2012-11-14 MX MX2014005759A patent/MX347164B/es active IP Right Grant
- 2012-11-14 PL PL12788410T patent/PL2780373T3/pl unknown
- 2012-11-14 SG SG11201402283PA patent/SG11201402283PA/en unknown
- 2012-11-14 SI SI201231692T patent/SI2780373T1/sl unknown
- 2012-11-14 HU HUE12788410A patent/HUE047437T2/hu unknown
- 2012-11-14 MY MYPI2019000058A patent/MY195289A/en unknown
- 2012-11-14 CN CN202011390234.3A patent/CN112812183A/zh active Pending
- 2012-11-14 UA UAA201406586A patent/UA115540C2/uk unknown
- 2012-11-14 PE PE2014000705A patent/PE20142041A1/es active IP Right Grant
- 2012-11-14 RS RSP20191179 patent/RS59248B1/sr unknown
- 2012-11-14 US US13/676,511 patent/US9023995B2/en active Active
- 2012-11-14 CA CA2852994A patent/CA2852994C/en active Active
- 2012-11-14 EA EA201400579A patent/EA031948B1/ru not_active IP Right Cessation
- 2012-11-14 EP EP12788410.4A patent/EP2780373B1/en active Active
- 2012-11-14 KR KR1020197030980A patent/KR102159109B1/ko active IP Right Grant
- 2012-11-14 PT PT127884104T patent/PT2780373T/pt unknown
- 2012-11-15 TW TW101142698A patent/TWI573804B/zh active
- 2012-11-15 AR ARP120104313A patent/AR089178A1/es active IP Right Grant
- 2012-11-16 UY UY0001034456A patent/UY34456A/es active IP Right Grant
-
2014
- 2014-04-04 ZA ZA2014/02491A patent/ZA201402491B/en unknown
- 2014-04-13 IL IL232100A patent/IL232100B/en active IP Right Grant
- 2014-04-29 CL CL2014001123A patent/CL2014001123A1/es unknown
- 2014-05-14 CO CO14103887A patent/CO7020871A2/es unknown
- 2014-05-16 PH PH12014501108A patent/PH12014501108B1/en unknown
- 2014-06-13 EC ECIEPI20144976A patent/ECSP14004976A/es unknown
-
2015
- 2015-04-01 US US14/676,365 patent/US10550189B2/en active Active
-
2018
- 2018-02-06 JP JP2018019080A patent/JP6719490B2/ja active Active
-
2019
- 2019-10-10 HR HRP20191835TT patent/HRP20191835T1/hr unknown
- 2019-11-12 CY CY20191101185T patent/CY1122278T1/el unknown
- 2019-12-17 US US16/717,413 patent/US20200231684A1/en active Pending
-
2020
- 2020-01-14 IL IL272035A patent/IL272035A/en unknown
- 2020-06-16 JP JP2020103873A patent/JP2020156506A/ja active Pending
-
2023
- 2023-05-26 LT LTPA2023518C patent/LTPA2023518I1/lt unknown
- 2023-05-31 FR FR23C1023C patent/FR23C1023I2/fr active Active
- 2023-05-31 NL NL301233C patent/NL301233I2/nl unknown
- 2023-06-01 FI FIC20230020C patent/FIC20230020I1/fi unknown
- 2023-06-05 HU HUS2300021C patent/HUS2300021I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2300021I1 (hu) | Anti-IL-36R antitestek | |
HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
IL259826A (en) | Anti-alphabetatisiar antibody | |
GB201103955D0 (en) | Antibodies | |
GB201112056D0 (en) | Antibodies | |
HK1187056A1 (zh) | 抗體 | |
HUE051068T2 (hu) | Interleukin-31 monoklonális ellenanyag | |
SG10201609665PA (en) | FcɣRIIb-SPECIFIC Fc ANTIBODY | |
TWI563004B (en) | Anti-hxcr1 antibody | |
EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
GB201116342D0 (en) | Antigen combinations |